Dr Zhao Yi Jing

Language

English, Hokkien, Mandarin

Gender

Female

Last updated 07 Dec 2023

Key Achievements

Former headache service lead at Singapore General Hospital and the National Neuroscience Institute
Introduced the use of CGRP monoclonal antibody treatment for headache in Singapore and Southeast Asia
One of the earliest doctors to use CGRP monoclonal antibody treatment (erenumab, fremanezumab and galcanezumab) for headache in Singapore

Experience

Dr Zhao Yi Jing is a neurologist at Mount Elizabeth Hospital, Singapore.

Her subspecialty interest is in headaches, including headaches in adults, adolescents and pregnancy. She also treats neurological conditions such as sleep-related issues, stroke, Parkinson’s disease, epilepsy, motor neuron disease, dementia and other neurological conditions.

Dr Zhao was a visiting neurology consultant at Khoo Teck Puat Hospital, Sengkang General Hospital and Changi General Hospital.

She graduated from the National University of Singapore (NUS) and became a member of the Royal College of Physicians, UK. She obtained her master’s degree at NUS. She started her neurology career practising at Singapore General Hospital and the National Neuroscience Institute.

Besides her clinical work, she was a clinical lecturer at Lee Kong Chian School of Medicine and Yong Loo Lin School of Medicine, and a clinical assistant professor at Duke-NUS Medical School.

She is a member of the Asian Regional Consortium Headache Society, Singapore Medical Council and Singapore Medical Association. She was also part of the founding committee of the Headache Society of Singapore, and is currently the vice-president and treasurer. She has conducted talks in regional headache meetings and has sat on the advisory board for new treatments in headache and migraine.

Dr Zhao has published research papers on headache conditions, including the novel calcitonin gene-related peptide (CGRP) therapies for headache and migraine. She served as the Singapore principal investigator in several regional clinical trials for the latest headache treatment using CGRP monoclonal antibodies and small molecules.

She received the Singapore Health Quality Service Award.

Research and publications

Zhao, Y., et al. (2023). Approach to headache disorders and the management of migraine: consensus guidelines from the Headache Society of Singapore, first edition (2023). Singapore Medical Journal.

Zhao, Y. J., Ong, J. J. Y., & Goadsby, P. J. (2020). Emerging Treatment Options for Migraine. Annals of the Academy of Medicine, Singapore, 49(4), 226–235.

Zhao, Y., Ho, K., & Wong, P. S. (2020). Early clinical experience with a monoclonal antibody against the calcitonin gene-related peptide receptor in adolescents with migraine: A case series. Proceedings of Singapore Healthcare, 29(3), 212–214.

Zhao, Y., Lim, J., & Wong, P. S. (2021). Diagnosis and management of headaches in the Emergency Department (ED) in adults and children. Neurology India, 69(7), 173.

Zhao, Y., et al. (2021). Randomised, controlled trial of erenumab for the prevention of episodic migraine in patients from Asia, the Middle East, and Latin America: The EMPOwER study. Cephalalgia, 41(13), 1285–1297.

Zhao, Y., Lo, Y. L., Wee, S. L., & Narasimhalu, K. (2020). Interictal hemodynamic abnormality during motor activation in sporadic hemiplegic migraine: An explorative study. Journal of the Neurological Sciences, 418, 117148.